172 related articles for article (PubMed ID: 35552420)
1. Empirical use of β-lactam/β-lactamase inhibitor combinations does not increase mortality compared with cloxacillin and cefazolin in methicillin-susceptible Staphylococcus aureus bacteraemia: a propensity-weighted cohort study.
Willekens R; Puig-Asensio M; Suanzes P; Fernández-Hidalgo N; Larrosa MN; González-López JJ; Rodríguez-Pardo D; Pigrau C; Almirante B
J Antimicrob Chemother; 2022 Jul; 77(8):2288-2295. PubMed ID: 35552420
[TBL] [Abstract][Full Text] [Related]
2. Are all beta-lactams similarly effective in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia?
Paul M; Zemer-Wassercug N; Talker O; Lishtzinsky Y; Lev B; Samra Z; Leibovici L; Bishara J
Clin Microbiol Infect; 2011 Oct; 17(10):1581-6. PubMed ID: 21073629
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of cefazolin versus cloxacillin as definitive antibiotic therapy for MSSA bacteraemia: results from a large multicentre cohort study.
Bai AD; Showler A; Burry L; Steinberg M; Ricciuto DR; Fernandes T; Chiu A; Raybardhan S; Science M; Fernando E; Tomlinson G; Bell CM; Morris AM
J Antimicrob Chemother; 2015 May; 70(5):1539-46. PubMed ID: 25614044
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of cloxacillin versus cefazolin for methicillin-susceptible
Burdet C; Loubet P; Le Moing V; Vindrios W; Esposito-Farèse M; Linard M; Ferry T; Massias L; Tattevin P; Wolff M; Vandenesch F; Grall N; Quintin C; Mentré F; Duval X; Lescure FX;
BMJ Open; 2018 Sep; 8(8):e023151. PubMed ID: 30173161
[TBL] [Abstract][Full Text] [Related]
5. Comparison of outcomes in patients with methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia who are treated with β-lactam vs vancomycin empiric therapy: a retrospective cohort study.
Wong D; Wong T; Romney M; Leung V
BMC Infect Dis; 2016 May; 16():224. PubMed ID: 27215201
[TBL] [Abstract][Full Text] [Related]
6. Cefazolin versus cloxacillin as definitive antibiotic therapy for methicillin-susceptible Staphylococcus aureus spinal epidural abscess: a retrospective cohort study.
Bai AD; Findlater A; Irfan N; Singhal N; Loeb M
Int J Antimicrob Agents; 2021 Nov; 58(5):106429. PubMed ID: 34469802
[TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness of β-lactam versus vancomycin empiric therapy in patients with methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia.
Wong D; Wong T; Romney M; Leung V
Ann Clin Microbiol Antimicrob; 2016 Apr; 15():27. PubMed ID: 27112143
[TBL] [Abstract][Full Text] [Related]
8. CAMERA2 - combination antibiotic therapy for methicillin-resistant Staphylococcus aureus infection: study protocol for a randomised controlled trial.
Tong SY; Nelson J; Paterson DL; Fowler VG; Howden BP; Cheng AC; Chatfield M; Lipman J; Van Hal S; O'Sullivan M; Robinson JO; Yahav D; Lye D; Davis JS;
Trials; 2016 Mar; 17():170. PubMed ID: 27029920
[TBL] [Abstract][Full Text] [Related]
9. Comparison of therapy with β-lactam/β-lactamase inhibitor combinations or carbapenems for bacteraemia of nonurinary source caused by ESBL-producing Escherichia coli or Klebsiella pneumoniae.
Luo H; Xiao Y; Hang Y; Chen Y; Zhu H; Fang X; Cao X; Zou S; Hu X; Xiong J; Zhong Q; Hu L
Ann Clin Microbiol Antimicrob; 2021 Sep; 20(1):63. PubMed ID: 34488786
[TBL] [Abstract][Full Text] [Related]
10. Clinical Outcomes of Daptomycin Versus Anti-Staphylococcal Beta-Lactams in Definitive Treatment of Methicillin-susceptible Staphylococcus aureus Bloodstream Infections.
Agnello S; Wardlow LC; Reed E; Smith JM; Coe K; Day SR
Int J Antimicrob Agents; 2021 Aug; 58(2):106363. PubMed ID: 34033912
[TBL] [Abstract][Full Text] [Related]
11. Daptomycin versus placebo as an adjunct to beta-lactam therapy in the treatment of Staphylococcus aureus bacteremia: study protocol for a randomized controlled trial.
Cheng MP; Lawandi A; Butler-Laporte G; Paquette K; Lee TC
Trials; 2018 May; 19(1):297. PubMed ID: 29843781
[TBL] [Abstract][Full Text] [Related]
12. Contemporary use of cefazolin for MSSA infective endocarditis: analysis of a national prospective cohort.
Herrera-Hidalgo L; Muñoz P; Álvarez-Uría A; Alonso-Menchén D; Luque-Marquez R; Gutiérrez-Carretero E; Fariñas MDC; Miró JM; Goenaga MA; López-Cortés LE; Angulo-Lara B; Boix-Palop L; de Alarcón A;
Int J Infect Dis; 2023 Dec; 137():134-143. PubMed ID: 37926195
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of empirical antibiotic treatments in methicillin-susceptible Staphylococcus aureus infective endocarditis: A post hoc analysis of a prospective French cohort study.
Lecomte R; Deschanvres C; Bourreau A; Ruffier d'Epenoux L; Le Turnier P; Gaborit B; Chauveau M; Michel M; Le Tourneau T; Bémer P; Corvec S; Boutoille D
Int J Infect Dis; 2024 May; 142():106989. PubMed ID: 38428479
[TBL] [Abstract][Full Text] [Related]
14. A large retrospective cohort study of cefazolin compared with flucloxacillin for methicillin-susceptible Staphylococcus aureus bacteraemia.
Davis JS; Turnidge J; Tong S
Int J Antimicrob Agents; 2018 Aug; 52(2):297-300. PubMed ID: 29499317
[TBL] [Abstract][Full Text] [Related]
15. Effect of Vancomycin or Daptomycin With vs Without an Antistaphylococcal β-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA Bacteremia: A Randomized Clinical Trial.
Tong SYC; Lye DC; Yahav D; Sud A; Robinson JO; Nelson J; Archuleta S; Roberts MA; Cass A; Paterson DL; Foo H; Paul M; Guy SD; Tramontana AR; Walls GB; McBride S; Bak N; Ghosh N; Rogers BA; Ralph AP; Davies J; Ferguson PE; Dotel R; McKew GL; Gray TJ; Holmes NE; Smith S; Warner MS; Kalimuddin S; Young BE; Runnegar N; Andresen DN; Anagnostou NA; Johnson SA; Chatfield MD; Cheng AC; Fowler VG; Howden BP; Meagher N; Price DJ; van Hal SJ; O'Sullivan MVN; Davis JS;
JAMA; 2020 Feb; 323(6):527-537. PubMed ID: 32044943
[TBL] [Abstract][Full Text] [Related]
16. Multicentre, randomised, open-label, phase IV-III study to evaluate the efficacy of cloxacillin plus fosfomycin versus cloxacillin alone in adult patients with methicillin-susceptible
Grillo S; Cuervo G; Carratala J; San-Juan R; Aguado JM; Morata L; Gomez-Zorrilla S; López-Contreras J; Gasch O; Gomila-Grange A; Iftimie S; Garcia-Pardo G; Calbo E; Boix-Palop L; Oriol I; Jover-Sáenz A; López-Cortés LE; Euba G; Aguirregabiria M; Garcia-Pais MJ; Gioia F; Paño JR; Pedro-Botet ML; Benítez RM; Pérez-Rodríguez MT; Meije Y; Loeches-Yagüe MB; Horna G; Berbel D; Domínguez MÁ; Padullés A; Cobo S; Hereu P; Videla S; Tebe C; Pallarés N; Miro JM; Pujol M;
BMJ Open; 2021 Aug; 11(8):e051208. PubMed ID: 34353808
[TBL] [Abstract][Full Text] [Related]
17. Cefazolin versus anti-staphylococcal penicillins for treatment of methicillin-susceptible Staphylococcus aureus bacteraemia: a narrative review.
Loubet P; Burdet C; Vindrios W; Grall N; Wolff M; Yazdanpanah Y; Andremont A; Duval X; Lescure FX
Clin Microbiol Infect; 2018 Feb; 24(2):125-132. PubMed ID: 28698037
[TBL] [Abstract][Full Text] [Related]
18. Comparative Effectiveness of Cefazolin Versus Nafcillin or Oxacillin for Treatment of Methicillin-Susceptible Staphylococcus aureus Infections Complicated by Bacteremia: A Nationwide Cohort Study.
McDanel JS; Roghmann MC; Perencevich EN; Ohl ME; Goto M; Livorsi DJ; Jones M; Albertson JP; Nair R; O'Shea AMJ; Schweizer ML
Clin Infect Dis; 2017 Jul; 65(1):100-106. PubMed ID: 28379314
[TBL] [Abstract][Full Text] [Related]
19. Risk Factors for Nephrotoxicity in Methicillin-Resistant Staphylococcus aureus Bacteraemia: A Post Hoc Analysis of the CAMERA2 Trial.
Legg A; Meagher N; Johnson SA; Roberts MA; Cass A; Scheetz MH; Davies J; Roberts JA; Davis JS; Tong SYC
Clin Drug Investig; 2023 Jan; 43(1):23-33. PubMed ID: 36217068
[TBL] [Abstract][Full Text] [Related]
20. β-Lactam Therapy for Methicillin-Susceptible Staphylococcus aureus Bacteremia: A Comparative Review of Cefazolin versus Antistaphylococcal Penicillins.
Li J; Echevarria KL; Traugott KA
Pharmacotherapy; 2017 Mar; 37(3):346-360. PubMed ID: 28035690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
